ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Silexion Therapeutics Corp
1.59
+0.0100
0.63%
盤後:
1.48
-0.1100
-6.92%
19:58 EST
成交量:
5.01萬
成交額:
7.97萬
市值:
497.14萬
市盈率:
-0.06
高:
1.64
開:
1.60
低:
1.54
收:
1.58
52周最高:
26.70
52周最低:
1.51
股本:
312.66萬
流通股本:
275.35萬
量比:
1.36
換手率:
1.82%
股息:
- -
股息率:
- -
每股收益(TTM):
-25.2122
每股收益(LYR):
-395.3595
淨資產收益率:
-771.23%
總資產收益率:
-77.60%
市淨率:
0.71
市盈率(LYR):
0.00
資料載入中...
總覽
公司
新聞資訊
公告
概念
沒有相關數據
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞資訊
Silexion Therapeutics Corp盤中異動 大幅下挫5.14%報1.66美元
市场透视
·
02/11
Silexion Therapeutics獲得德國衞生部門對其胰腺癌2/3期臨牀試驗設計的積極反饋
美股速递
·
2025/12/02
Silexion Therapeutics 成功完成 Sil204 的毒理學研究,為胰腺癌的 2/3 階段臨牀試驗做好準備
美股速递
·
2025/11/25
Silexion Therapeutics Corp公布積極的人體細胞係數據,證實Sil204的泛KRAS活性,抑制率高達99.7%,並首次在胃癌中顯示療效
美股速递
·
2025/09/30
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/SLXN"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"SLXN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","market":"US","secType":"STK","nameCN":"Silexion Therapeutics Corp","latestPrice":1.59,"timestamp":1771016400000,"preClose":1.58,"halted":0,"volume":50099,"hourTrading":{"tag":"盘后","latestPrice":1.48,"preClose":1.59,"latestTime":"19:58 EST","volume":4345,"amount":6724.25,"timestamp":1771030726920,"change":-0.11,"changeRate":-0.069182,"amplitude":0.075472},"delay":0,"changeRate":0.006329113924050638,"floatShares":2753490,"shares":3126642,"eps":-25.2122,"marketStatus":"休市中","change":0.01,"latestTime":"02-13 16:00:00 EST","open":1.6,"high":1.6361,"low":1.54,"amount":79729.452362,"amplitude":0.060823,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-25.2122,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1771318800000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.58,"preHourTrading":{"tag":"盘前","latestPrice":1.63,"preClose":1.58,"latestTime":"08:36 EST","volume":9,"amount":14.789999700000001,"timestamp":1770989761336,"change":0.05,"changeRate":0.031646,"amplitude":0.025316},"postHourTrading":{"tag":"盘后","latestPrice":1.48,"preClose":1.59,"latestTime":"19:58 EST","volume":4345,"amount":6724.25,"timestamp":1771030726920,"change":-0.11,"changeRate":-0.069182,"amplitude":0.075472},"volumeRatio":1.3569685372220825},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","floatShares":2753490,"roa":"-77.60%","roe":"-771.23%","lyrEps":-395.359461,"volumeRatio":1.3569685372220825,"shares":3126642,"dividePrice":0,"high":1.6361,"amplitude":0.060823,"preClose":1.58,"low":1.54,"week52Low":1.51,"pbRate":"0.71","week52High":26.7,"institutionHeld":0,"latestPrice":1.59,"eps":-25.2122,"divideRate":0,"volume":50099,"delay":0,"ttmEps":-25.2122,"open":1.6,"prevYearClose":1.92,"prevWeekClose":1.61,"prevMonthClose":1.83,"prevQuarterClose":1.92,"fiveDayClose":1.61,"twentyDayClose":2.44,"sixtyDayClose":2.58},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLXN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-07-29","symbol":"SLXN","defaultRemindTime":1753795800000,"type":"split","dateTimestamp":1753761600000,"forFactor":15,"toFactor":1,"ratio":15},{"market":"US","date":"2024-11-29","symbol":"SLXN","defaultRemindTime":1732890600000,"type":"split","dateTimestamp":1732856400000,"forFactor":9,"toFactor":1,"ratio":9},{"market":"US","date":"2024-08-13","symbol":"SLXN","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLXN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLXN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1765861200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLXN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLXN","date":"2026-02-13","current":-0.063065,"percent":0.233831,"low":-1.070842,"twenty":-0.597129,"median":-0.417327,"eighty":-0.124456,"high":-0.075397,"avg":-0.40344,"sd":0.251745,"marketCap":4940094},"quantilePoints":[{"date":"2025-05-02","current":-0.511745,"twenty":-0.505522,"median":-0.478123,"eighty":-0.462658,"marketCap":8414615},{"date":"2025-05-09","current":-0.508623,"twenty":-0.511745,"median":-0.504017,"eighty":-0.475134,"marketCap":8363285},{"date":"2025-05-16","current":-0.49368,"twenty":-0.511295,"median":-0.503966,"eighty":-0.488849,"marketCap":8117579},{"date":"2025-05-23","current":-0.504427,"twenty":-0.509135,"median":-0.49826,"eighty":-0.470682,"marketCap":8294286},{"date":"2025-05-30","current":-0.491275,"twenty":-0.511407,"median":-0.49826,"eighty":-0.475032,"marketCap":8078030},{"date":"2025-06-06","current":-0.471573,"twenty":-0.511407,"median":-0.49368,"eighty":-0.475196,"marketCap":7754067},{"date":"2025-06-13","current":-0.453201,"twenty":-0.509647,"median":-0.491403,"eighty":-0.471409,"marketCap":7451983},{"date":"2025-06-20","current":-0.41963,"twenty":-0.506945,"median":-0.488844,"eighty":-0.464552,"marketCap":6899984},{"date":"2025-06-27","current":-0.415025,"twenty":-0.504283,"median":-0.484008,"eighty":-0.449824,"marketCap":6824252},{"date":"2025-07-03","current":-0.415025,"twenty":-0.504048,"median":-0.478123,"eighty":-0.41963,"marketCap":6824252},{"date":"2025-07-11","current":-0.42265,"twenty":-0.503966,"median":-0.474592,"eighty":-0.417174,"marketCap":6949630},{"date":"2025-07-18","current":-0.440049,"twenty":-0.503178,"median":-0.468758,"eighty":-0.415025,"marketCap":7235727},{"date":"2025-07-25","current":-0.430889,"twenty":-0.49932,"median":-0.464408,"eighty":-0.415332,"marketCap":7085105},{"date":"2025-08-01","current":-0.509697,"twenty":-0.49932,"median":-0.462719,"eighty":-0.415332,"marketCap":8380951},{"date":"2025-08-08","current":-0.292718,"twenty":-0.495931,"median":-0.452101,"eighty":-0.414513,"marketCap":4813156},{"date":"2025-08-15","current":-0.251096,"twenty":-0.493608,"median":-0.447572,"eighty":-0.409037,"marketCap":4128768},{"date":"2025-08-22","current":-0.231991,"twenty":-0.492964,"median":-0.436237,"eighty":-0.386752,"marketCap":3814623},{"date":"2025-08-29","current":-0.263889,"twenty":-0.49148,"median":-0.430786,"eighty":-0.303498,"marketCap":4339133},{"date":"2025-09-05","current":-0.238814,"twenty":-0.491275,"median":-0.423383,"eighty":-0.280777,"marketCap":3926818},{"date":"2025-09-12","current":-0.168193,"twenty":-0.491275,"median":-0.420859,"eighty":-0.25246,"marketCap":2765601},{"date":"2025-09-19","current":-0.12316,"twenty":-0.486413,"median":-0.417583,"eighty":-0.247343,"marketCap":2025116},{"date":"2025-09-26","current":-0.128618,"twenty":-0.486106,"median":-0.415793,"eighty":-0.244955,"marketCap":2114871},{"date":"2025-10-03","current":-0.128618,"twenty":-0.484008,"median":-0.415025,"eighty":-0.242737,"marketCap":2114871},{"date":"2025-10-10","current":-0.136465,"twenty":-0.48104,"median":-0.413413,"eighty":-0.231991,"marketCap":2243896},{"date":"2025-10-17","current":-0.121454,"twenty":-0.478123,"median":-0.409651,"eighty":-0.138853,"marketCap":1997067},{"date":"2025-10-24","current":-0.114972,"twenty":-0.478123,"median":-0.401489,"eighty":-0.132201,"marketCap":1890482},{"date":"2025-10-31","current":-0.112584,"twenty":-0.477611,"median":-0.386196,"eighty":-0.129301,"marketCap":1851214},{"date":"2025-11-07","current":-0.097914,"twenty":-0.471573,"median":-0.312505,"eighty":-0.127936,"marketCap":1609995},{"date":"2025-11-14","current":-0.097914,"twenty":-0.471163,"median":-0.292718,"eighty":-0.123842,"marketCap":1609995},{"date":"2025-11-21","current":-0.080173,"twenty":-0.468758,"median":-0.272333,"eighty":-0.121795,"marketCap":1318288},{"date":"2025-11-28","current":-0.096549,"twenty":-0.467039,"median":-0.257237,"eighty":-0.120362,"marketCap":1587556},{"date":"2025-12-05","current":-1.070842,"twenty":-0.471245,"median":-0.259284,"eighty":-0.119953,"marketCap":9902075},{"date":"2025-12-12","current":-1.0279,"twenty":-0.478706,"median":-0.282158,"eighty":-0.120362,"marketCap":9504991},{"date":"2025-12-19","current":-0.821644,"twenty":-0.486167,"median":-0.30227,"eighty":-0.120704,"marketCap":7597740},{"date":"2025-12-26","current":-0.797975,"twenty":-0.491377,"median":-0.316599,"eighty":-0.121181,"marketCap":7378875},{"date":"2026-01-02","current":-0.6492,"twenty":-0.495368,"median":-0.386196,"eighty":-0.12159,"marketCap":6003152},{"date":"2026-01-09","current":-0.710063,"twenty":-0.504027,"median":-0.401489,"eighty":-0.122205,"marketCap":6565948},{"date":"2026-01-16","current":-0.825025,"twenty":-0.510588,"median":-0.409651,"eighty":-0.122955,"marketCap":7629006},{"date":"2026-01-23","current":-0.726969,"twenty":-0.515839,"median":-0.412313,"eighty":-0.12316,"marketCap":6722280},{"date":"2026-01-30","current":-0.662725,"twenty":-0.574408,"median":-0.414769,"eighty":-0.123296,"marketCap":6128218},{"date":"2026-02-06","current":-0.510569,"twenty":-0.606596,"median":-0.415025,"eighty":-0.12391,"marketCap":4721229},{"date":"2026-02-13","current":-0.534237,"twenty":-0.597129,"median":-0.417327,"eighty":-0.124456,"marketCap":4940094}],"updateTime":1771088646165},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLXN\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610620679","title":"Silexion Therapeutics Corp盤中異動 大幅下挫5.14%報1.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610620679","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610620679?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 01:34","pubTimestamp":1770744859,"startTime":"0","endTime":"0","summary":"北京时间2026年02月11日01时34分,Silexion Therapeutics Corp股票出现波动,股价急速下挫5.14%。截至发稿,该股报1.66美元/股,成交量2.9551万股,换手率0.95%,振幅6.86%。Silexion Therapeutics Corp股票所在的生物技术行业中,整体涨幅为0.14%。Silexion Therapeutics Corp公司简介:Silexion Therapeutics Corp 是一家临床阶段的肿瘤学生物技术公司,致力于发现和开发KRAS驱动癌症的专有治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211013419a6eb6aac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211013419a6eb6aac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4539","SLXN","LENZ","BK4007"],"gpt_icon":0},{"id":"1108369243","title":"Silexion Therapeutics獲得德國衞生部門對其胰腺癌2/3期臨牀試驗設計的積極反饋","url":"https://stock-news.laohu8.com/highlight/detail?id=1108369243","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108369243?lang=zh_tw&edition=fundamental","pubTime":"2025-12-02 21:01","pubTimestamp":1764680504,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics获得德国卫生部门对其胰腺癌2/3期临床试验设计的积极反馈","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"1186776790","title":"Silexion Therapeutics 成功完成 Sil204 的毒理學研究,為胰腺癌的 2/3 階段臨牀試驗做好準備","url":"https://stock-news.laohu8.com/highlight/detail?id=1186776790","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186776790?lang=zh_tw&edition=fundamental","pubTime":"2025-11-25 22:16","pubTimestamp":1764080200,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics 成功完成了 Sil204 的毒理学研究,这是一种下一代 RNA 静默疗法,为即将进行的胰腺癌 2/3 阶段临床试验做好了准备。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"gpt_icon":0},{"id":"1183341465","title":"Silexion Therapeutics Corp公布積極的人體細胞係數據,證實Sil204的泛KRAS活性,抑制率高達99.7%,並首次在胃癌中顯示療效","url":"https://stock-news.laohu8.com/highlight/detail?id=1183341465","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183341465?lang=zh_tw&edition=fundamental","pubTime":"2025-09-30 20:40","pubTimestamp":1759236051,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp宣布公布积极的人体细胞系新数据,证实了其候选药物Sil204的泛KRAS活性。数据显示,该药物的抑制率高达99.7%,并首次在胃癌治疗中展现出积极效果。\n这项最新研究结果进一步验证了Sil204作为泛KRAS抑制剂的潜力,为该公司在肿瘤治疗领域的药物开发提供了重要支撑。特别值得关注的是,这是该药物首次在胃癌细胞中显示出治疗活性,为胃癌患者带来了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/SLXN\",params:#limit:6,delay:false,,,undefined,":[]}}